中生北控
BioSino

BIOSINO BIO-TECHNOLOGY
AND SCIENCE INCORPORATION

ENVIRONMENTAL SOCIAL AND GOVERNANCE REPORT

2025 ENVIRONMENTAL SOCIAL AND GOVERNANCE REPORT

CONTENTS

About this Report 1
Message from the Chairman 2
2025 Performance Highlights 3
Key Events of 2025 5
About BioSino 7
Recognition and Awards 8

01 Governance
- Board Diversity 9
- Governance Structure 9
- Internal Control and Risk Management 10
- Business Ethics and Anti-corruption Policy 11
- Business Information Security 11
- Business Information Disclosure and Security 12
- Stakeholder Identification and Engagement 12
- Materiality Issue Determination 14

02 Product Research and Development and Innovation
- Healthcare Inclusivity 16
- Technology and Innovation 17
- Product and Service Quality 20

03 Green and Low-carbon-Development
- Environmental Protection Policies and Objectives 24
- Addressing Climate Change 24
- Low-carbon Office 28
- Emission Management, the Utilization of Resource and Energy 29

04 Talent Development
- Corporate culture and the concept of employing 31
- Talent Training and Retention 31
- Occupational Health and Safety 36

05 Ecological Co-construction
- Strategic Cooperation 37
- Empowering Teams and Industry Growth 38
- Supply Chain ESG Management 38
- Participate in the Formulation of Industry Standards and Groups Standards 41
- Exhibition Appearances 42
- Community Involvement 43

Index Table of HKEX ESG Reporting Code 44
Reader Feedback 47

ABOUT THIS REPORT

Overview

This report is the fifth Environmental, Social and Governance Report issued by Biosino Bio-Technology and Science Incorporation, (the "Company, together with its subsidiaries, the "Group", "Biosino", "We", or "us"), which comprehensively reflects the Company's performance in ESG. Unless otherwise stated, the reporting period covers the performance of the financial year from January 1, 2025 to December 31, 2025 (the "Reporting Period"). Where appropriate, certain related information outside of the Reporting Period is included for reference.

Report methodology

This report is prepared in accordance with Appendix C2 "Environmental, Social and Governance Reporting Code" to the GEM Listing Rules as amended effective 1 January 2025. For climate-related disclosures, it refers to the enhanced requirements under Part D of Appendix C2 and the TCFD recommendations. Where applicable, we have made reference to IFRS S2 Climate-related Disclosures in preparing relevant climate-related disclosures. In addressing climate change disclosure, reference is made to The Stock Exchange of Hong Kong Limited (the "Stock Exchange")'s "Guidance on the Recommended Disclosure of Climate-related Information according to the TCFD Recommendations".

Report scope

The policies and data provided in this report cover the Company and its subsidiaries, and the scope of the report is consistent with the annual report. The data and cases in this report are mainly from the Company's statistical reports and relevant documents. The disclosure boundary is: (a) Subsidiaries with consolidated financial statements; (b) Subsidiaries actually controlled; (c) Entities that have been put into operation for two natural years or more. The Board of Directors promises that there are no false records or misleading statements in this report, and is responsible for the authenticity, accuracy and completeness of its contents.

Report language

The report is drafted in English and Chinese. In the event of any discrepancy between the two verisons, the English version shall prevail.

Confirmation and approval

This report was approved by the Board on March 31, 2026.

Acquisition method

This report is provided in both paper and electronic forms. The electronic version of this report can be viewed and downloaded from the official website of Biosino and published on the website of the Stock Exchange.

MESSAGE FROM THE CHAIRMAN

Dear Shareholders, Investors, Colleagues, Business Partners, and Friends from all Sectors of Society,

On behalf of the Board of Directors of Biosino Bio-Technology and Science Incorporation, I am pleased to present the Group's 2025 Environmental, Social and Governance "ESG" Report. This report shares with you our practical results and future direction on the path toward sustainable development.

In 2025, the global in vitro diagnostic "IVD" industry continued to face the dual challenges of accelerated technological evolution and structural market transformation. Amid a complex and dynamic environment, we firmly believe that only through innovation-driven breakthroughs and win-win collaboration can we open up new horizons in times of uncertainty. ESG is not merely a disclosure requirement, but a core capability underpinning the Company's long-term development. The Group has consistently integrated environmental, social and governance principles into its corporate strategy, operational management and corporate culture, striving to establish a sustainable growth model that balances economic performance, social value and environmental responsibility.

In terms of technological innovation, we continued to enhance our independent research and development system, strengthen collaboration among industry, academia and research institutions, and promote the upgrading of products and solutions toward greater intelligence, system integration and higher quality. We believe that truly meaningful innovation lies not only in technological breakthroughs, but also in effectively responding to clinical needs, improving testing efficiency and enhancing accessibility to healthcare services. Looking ahead, we will continue to drive corporate development through innovation and provide more competitive products and comprehensive solutions to support the advancement of the healthcare industry.

With respect to corporate governance, the Board has continuously refined the ESG governance structure, optimized risk management and internal control mechanisms, and reinforced a culture of integrity and compliance. We uphold high standards of transparency and accountability to ensure steady operations while safeguarding the long-term interests of shareholders and stakeholders.

In fulfilling our social responsibilities, we adhere to a people-oriented philosophy, placing strong emphasis on employees' career development and physical and mental well-being, and fostering a diverse, inclusive and safe working environment. At the same time, we actively participate in public welfare initiatives and healthcare support programs, facilitating the broader accessibility of quality medical resources and contributing to greater healthcare equity. We firmly believe that corporate success should progress hand in hand with social advancement.

Environmental responsibility remains a key focus of our sustainable development strategy. We continue to promote green and low-carbon operations, enhance energy efficiency, optimize resource utilization, and explore pathways toward carbon reduction. By incorporating climate-related risks and opportunities into our long-term planning, we aim to strengthen our operational resilience while contributing to the industry's transition toward sustainable development.

Looking forward, we will continue to take "Breakthrough and Win-Win" as our guiding development theme, deepen our innovation deployment, enhance governance standards and strengthen responsibility management. Together with our partners, we aim to build an open, collaborative and symbiotic healthcare ecosystem. We are confident that by remaining true to our original aspiration and embracing transformation, Biosino will steadily advance in the evolving landscape of the new era and continue to create long-term value for society.

Finally, I would like to express my sincere gratitude to all employees for their dedication and hard work, to our partners for their trust and support, and to all sectors of society for their continued attention and supervision. Let us move forward together on the journey of sustainable development, safeguard health through technology, and give back to society through responsible business practices..

2025 PERFORMANCE HIGHLIGHTS

01 Financial Performance

Annual revenue for 2025:

184.023

million yuan



02 Corporate Governance

10

Board members

16

ESG committee members

24

Significant ESG issues.

100%

Board member participation in business ethics training courses

7

Board meetings

2

Shareholder meetings



03 Product Innovation

26.82 million yuan

R&D investment for 2025

28

Number of R&D center staff

82

Granted invention patents

43

Granted utility model patents

15

Granted design patents

31

Software copyrights

38

Trademarks

48

Published papers

281

Product registration certificates held



04 Green and Low Carbon


Total carbon emissions (Scope 1+Scope 2) for 2025

1246.90 tCO_2e

Carbon emission intensity

0.0678

tCO_2e per ten thousand RMB




05 Ecological Co-construction

2

Formulation of industry standard and group standard

7

International and domestic exhibitions



06 Employee Development

Total number of employees

408

Percentage of female employees

45.6%

Employee training coverage rate

100%

Anti-corruption training for all employees

100%

Safety education training coverage rate

100%

Safety risk protection training coverage rate

100%

Occupational injury insurance coverage rate for employees

100%

Employee health check coverage rate

100%



KEY EVENTS OF 2025

Corporate Governance

- Awarded the title of "Specialized, Refined, Distinctive and Innovative" SME in Beijing
- Selected as a Leading Enterprises in Enterprise Innovation Credit in Beijing for 2025
- Obtained CNAS accreditation for the Biosino reference laboratory
- Obtained the TUV Medical Device Quality Management System Certification Certificate

Product Innovation

- The Pathfast fully automated point-of-care cardiac marker detector made its debut at the China Heart Congress
- The South Sichuan Institute of Translational Medicine and Biosino Precision Medicine jointly established a joint laboratory
- Obtained authorization for 4 invention patents and 1 design patent
- Get the 4-laser 21-color BioCyte X high-end (clinical version) flow cytometer was approved for listing
- The flow cytometry absolute counting tube was approved for listing
- Obtained the NMPA class III registration certificate for the novel coronavirus antigen detection kit (colloidal gold method)
- Obtained approval for the calcium assay kit (arsenazo III method)
- Successfully launched the new multi-cancer early screening product "One Tube Safe"
- Introduced new products under the polygonatum series and wellness tea series
- The AutoProSample A960 Fully Automated Flow Cytometry Workstation was showcased at MEDICA 2025
- Completed variation registrations for 37 biochemical products
- The Total Bile Acid Quality Control product obtained a Class II medical device registration certificate from the Beijing Medical Products Administration
- Participated in the development of the expert consensus on multi-cancer combined screening

Green and Low Carbon

- Since the smart power distribution room was put into operation, it has been operating safely and stably, saving 200,000 yuan in electricity bills and reducing approximately 140 tons of CO_2e
- Since the automatic steam operation and maintenance system was put into use, it has been operating safely and stably.

Save about electricity **200,000**

Reduce CO_2 emissions **140**t

Ecological Co-construction

- Showcased newly launched products at the Dubai International Laboratory Equipment Exhibition
- Showcased newly launched products at the China Medical Equipment Conference and Medical Equipment Exhibition in Chongqing
- Showcased newly launched products at the 22nd China Association of Clinical Laboratory Practice Expo (CACLP) held in Hangzhou
- Showcased newly launched products at the 22nd China Heart Congress (CHC 2025) in Beijing
- Showcased newly launched products at the 19th Academic Conference on Laboratory Medicine organised by the Beijing Medical Association
- Participated in the CCLM 2025 Cardiovascular Laboratory Medicine Conference held in Guangzhou
- Showcased newly launched products at MEDICA in Düsseldorf, Germany, one of the world's leading trade fairs for the medical industry
- Biosino entered into a strategic cooperation with China Resources Technology (Beijing) Co., Ltd.
- Biosino entered into a strategic cooperation with BIOBASE Group
- Biosino Medical Biotechnology (Shanxi) Co., Ltd. was established
- The Institute of Biophysics, Chinese Academy of Sciences – Biosino In Vitro Diagnostic Engineering Research Center was established
- Hosted the Precision Medicine Testing Summit Forum
- The Ghana Health Service and the West African Health Community Association visited the Biosino Technology Achievements Transformation Center for exchange and discussions

Giving back to Society

- Participation in Changping District's winter snow removal and de-icing volunteer service initiative.

ABOUT BIOSINO

Biosino was established in 1988 and was listed on the GEM of The Stock Exchange in Hong Kong in 2006 (stock code: 8247). The Group is a high-tech enterprise founded by the Institute of Biophysics, Chinese Academy of Sciences, mainly engaged in the research and development, production, sales, and service of in-vitro diagnostic (IVD) products. The history of the Company's reagent production can be traced back to the three-link preparation group of the Institute of Biophysics in 1973. The Company's development has been guided by addressing the needs of people's livelihood, actively promoting the development of the national IVD industry, building an independent innovation system that combines production, learning, research, and application, and exploring an "international, group, and composite" business model, constructinga "systematic, serialized, integrated, and intelligent" four-in-one full industrial chain, enhancing core competitiveness, and establishing a certain influence in the industry. Since the launch of China's enzymatic single and double biochemical reagents, Biosino has established a complete biochemical detection series product platform through years of product accumulation, expanded immunology, molecular, flow cytometry, and other in-vitro diagnostic series products, and is committed to creating a comprehensive clinical diagnosis and treatment solution. Currently, it has obtained approximately 281 registration certificates for in-vitro diagnostic reagent products, mainly covering twelve categories of biochemical testing items such as liver function, kidney function, lipids, cardiovascular, diabetes, and rheumatism, and is one of the domestic manufacturers with the most complete range of biochemical diagnostic reagent products.

The Company jointly established an in-vitro diagnostic engineering research center with the Institute of Biophysics, Chinese Academy of Sciences, and has cooperated with internationally renowned companies. Since 2012, it has cooperated with the international brand Abbott to launch the "China-Abbott" brand biochemical reagents, and has been cooperating for more than ten years. Since 2018, it has formally signed a cooperation agreement with Meidensha Corporation (now affiliated with the PHC Corporation Group), formerly under the Japanese Mitsubishi Corporation, to jointly promote the development of ultra-sensitive cardiac markers and the POCT platform PATHFAST bedside chemiluminescence immunoassay system in China.

Biosino established a reference laboratory in 2006. During a period when China had not yet established traceability standards, it carried out the establishment of reference methods and value transfer for enzyme projects according to international standards. The reference laboratory establishes and operates a laboratory quality management system in accordance with the ISO/IEC 17025:2017 and ISO 15195:2018 standards and has obtained the accreditation certificate issued by CNAS. Currently, the Biosino reference laboratory has platforms such as ultraviolet spectrophotometry, liquid chromatography, and liquid chromatography-mass spectrometry, and can carry out reference measurement procedures for more than ten projects such as enzymology, small molecule metabolites, lipids, and vitamins, and provides reference measurement services to the outside world. In addition, the reference laboratory carries out reference measurement assignment work for clinical laboratory test result mutual recognition samples in the Beijing-Tianjin-Hebei-Shandong region and some items of Beijing's accuracy verification samples, and cooperates with institutions such as the China Institute for Food and Drug Control, the National Institute of Metrology, and the Beijing Medical Device Inspection Institute to carry out joint assignment and verification work for national standard substances and national standard products. As a member unit of TC136, it participates in the drafting and verification work of national and industry standards of TC136.

After years of efforts, the reference laboratory has formed a complete traceability and value transfer system, established the traceability of more than 100 testing items of the Company, and has "instrument-reagent-reference material systematic products", which has played a positive role in improving the accuracy, reliability, and comparability of test results. Fifty years of changing seasons, wind and rain; fifty years of day and night alternation, forging ahead. As an experiencer and promoter of the development of the national IVD industry, Biosino has always been committed to the health of the people's lives, adhering to innovation, and steadily developing in the industry with solid achievements. The Company shoulders the corporate mission of "beautifying life with science and technology", with the corporate vision of "becoming an internationally competitive participant in the IVD industry", adhering to the corporate values of "being an honest person and being the first in the world", and carrying forward the corporate spirit of "integrity, cooperation, dedication, and innovation", focusing on the field of in-vitro diagnostics, focusing on innovation, and lean management. Biosino will continue to strengthen its scientific and technological innovation capabilities and capacity building, and continue to provide more precise solutions for the IVD industry with new products, new technologies, and new models, contributing BIOSINO solutions, BIOSINO wisdom, and Biosino strength to global health!

Corporate Mission: To beautify life through technology.

Corporate Vision: To become a leader in the IVD industry with international competitiveness.

Corporate Values: Be honest and place integrity first.

Corporate Spirit: Integrity, cooperation, dedication, innovation.

Business Philosophy: Focus on the core business, build the industrial chain, and develop competitiveness.

Talent Philosophy: Believe in the future, embrace change, transform oneself, create value.

Quality Policy: High quality, efficiency, craft premium reagents; accurate, stable, measure vital functions.

RECOGNITION AND AWARDS

























GOVERNANCE

During the Reporting Period, the Company has complied with all applicable code provisions set out Appendix C1 "Corporate Governance Code" of the "GEM Listing Rules" of the Stock Exchange and adopted the recommended best practices listed there in where appropriate.
The Company has established the "Biosino Bio-Technology and Science Incorporation Articles of Association" and, in accordance with the "Board of Directors Meeting Rules," "Shareholders' Meeting Rules," and "Supervisory Board Meeting Rules" and other system requirements, regularly convened shareholder meetings, board meetings, and supervisory board meetings for management decision-making and operational oversight. In this fiscal year, the Company's decision-making and supervisory bodies, including the shareholders' meeting, board of directors, and supervisory board, have strictly managed decision-making and operational oversight in accordance with normative operating rules and internal systems. The board of directors convened 7 times, deliberating on 30 proposals in total; the shareholders' meeting was held twice, with a total of 13 proposals.

GOVERNANCE STRUCTURE

The Company has established a governance structure composed of the Shareholders' Meeting, the Board of Directors and its special committees, and the senior management team. The Board of Directors has established three committees: the Remuneration Committee, the Nomination Committee, and the Audit Committee, to oversee specific areas of the Company's affairs.

BOARD DIVERSITY

On January 8, 2019, the Board of Directors adopted the "Board Member Diversity Policy," which specifies that the selection of Board members will be based on a range of diversity categories, taking into account the Company's business model and specific needs. This includes, but is not limited to, gender, age, race, language, cultural background, educational background, industry experience, and professional experience.
Currently, the Board consists of 3 executive directors, 3 non-executive directors, and 4 independent non-executive directors. In terms of educational background among the Board members, there are 5 with doctoral degrees, 4 with master's degrees, and 1 with a bachelor's or other degree The current 10 directors are professionals with extensive experience in fields such as biological sciences, risk management, accounting, and law.

Board Members:

- percentage with Doctoral Degrees: 50%
- percentage with Master's Degrees or Higher: 90%



BOARD OF DIRECTORS' ESG STATEMENT

Biosino has established an ESG control structure covering three levels: decision-making level, management level and executive level. The Board is the decision-making level of ESG and the highest decision-making body of ESG. The ESG Committee of the board of directors is responsible for formulating the Company's ESG strategic policy, reviewing and making decisions on major ESG matters of the Company, regularly supervising and inspecting the progress of ESG related matters, fulfilling the ESG work requirements put forward by the Listing Supervision Department to the Board, and providing support for ESG decisions of the Board. At the same time, timely and accurately identifying the demands of various stakeholders, carrying out evaluation, and determining and revising material ESG issues. At the same time, we would discuss relevant issues, including but not limited to product quality,climate-related risks and opportunities (including Scope 1 and Scope 2 GHG emissions as mandated), anti-corruption and other fields, and respond to the demands of various stake holders.
The chairman takes charge of the ESG Committee and is responsible for presiding over the work of the Committee. The Secretary of the Board and all senior executives of the Company form the ESG leading group to formulate the Company's ESG management system, monthly inspect the implementation of the Company's ESG work, and regularly report the work progress to the ESG Committee. All departments of Biosino dispatch a representative to form an ESG working group to implement the decisions of the management and be responsible for the implementation of ESG objectives. On April 15, 2022, the chairman of the Board, Mr. Wu Lebin announced the establishment of the ESG Committee and the executive group under the Board, and held the deployment meeting of the Company's ESG and carbon assessment, which conducted on-site discussion and work deployment on important topics, annual objectives and future implementation plans of ESG.

The main responsibilities of the ESG Committee include:	Develop ESG vision, strategy and policy; monitor the implementation of ESG strategy; monitor the expenditure of ESG work; supervise the Company's external communication and dissemination; review the annual ESG report and make recommendations to the board of directors for approval.
The main responsibilities of ESG management include:	Regularly carry out stakeholder communication, clarify the annual ESG focus, continuously improve and enrich the Company's ESG development strategy and development plan, and continuously follow up the implementation of ESG related matters valued by stakeholders.
The main responsibilities of ESG executive layer include:	Around the Company's mission and vision, take specific improvement measures on the Company's compliance with business norms, green and low-carbon operation, product technology innovation, promoting supply chain development, protecting employees' rights and interests and supporting social development to ensure the completion of the annual ESG goal.

ESG Organizational structure



INTERNAL CONTROLS AND RISK MANAGEMENT

The Board of Directors is responsible for maintaining an appropriate and effective internal control and risk management system to protect the interests of the Company and its shareholders. It regularly reviews and supervises the effectiveness of the internal control and risk management systems to ensure they are comprehensive and adequate. The related internal audit functions performed by the Board include establishing formal arrangements for applying financial reporting and internal control principles in accounting and financial matters to ensure compliance with the Listing Rules and all relevant laws and regulations; the Company appoints external consultants to review the areas defined by the Audit Committee. The existing organizational structure and close supervision by management, along with the appointment of external consultants, enable the Company to maintain sufficient risk management and internal controls. The Board will from time to time review the necessity of establishing an internal audit function and may establish an internal audit team when needed. The Company has developed related system documents such as the "Risk Management Control Procedures" and "Financial System Manual," which define the processes and methods for risk management.

Risk Identification

The Company regularly organizes meetings to discuss financial, operational, compliance control, and risk management processes. At the same time, it hires independent external auditing institutions, and third-party professional companies assess the risks faced by the Company and the response measures to ensure that effective measures have been taken to identify existing and potential risks, including compliance risks, operational risks, and business continuity risks, and further clarify the priorities of risk management based on the potential impact and likelihood of risks.

Specialized Risk Training and Dissemination

To enhance employees' awareness of compliance and risk management, the Company regularly conducts diversified specialized risk training and dissemination for all employees, covering key areas such as compliance, information security, product quality, and ESG, to ensure that all employees are fully understand and comply with internal compliance and risk control policies and procedures. During the reporting period, the Company conducted more than 100 training sessions on laws and regulations, risk management, anti-corruption, ESG, etc.

Risk Reporting Mechanism

On the basis of the whistleblowing mechanism, the Company has set up a suggestion box (yijianxiang@zhongsheng.com.cn) to encourage employees to proactively identify risks related to business ethics and report any identified risks to the Company. All reports are handled confidentially and in accordance with the Company's whistleblowing policy.

BUSINESS ETHICS AND ANTI-CORRUPTION POLICY

Biosino has issued the anti-corruption policy to fully support and uphold the high standards of integrity, honesty and fair competition in carrying out the Company's business, and will never tolerate any form of bribery or corruption. The policy clearly states that employees should abide by all applicable anti bribery laws, especially the Hong Kong bribery Prevention 0rdinance, the British Anti Bribery Act, the People's Republic of China ("PRC") Criminal Law and the PRC Anti Unfair Competition Act, and common law relating to crimes to avoid misconduct of public officials. The Company regularly provides anti-corruption training and briefings for all employees. The training courses include online courses and on-site demonstrations. The Company actively encourages employees to report any concerns about bribery and corruption. All business departments keep records of suspected and actual accidents, and report relevant statistics to the financial controller of the Company on a quarterly basis. During the Reporting Period, the Company is not aware of any material corruption incidents and no concluded legal cases regarding corrupt practices were identified.

The Board of Directors is responsible for the implementation of anti-bribery and anti-corruption efforts within the group. The executive directors of the Company are responsible for ensuring the effective implementation and monitoring of any significant bribery or corruption activities within the group. During the reporting period, Biosino launched two specialized training sessions on anti-commercial bribery and legal regulations, sharing the training materials with all employees. The training content mainly included the definition of commercial bribery, forms and common misconceptions of commercial bribery, liability and risk control in commercial bribery.

Biosino maintains an open, trusting, and respectful atmosphere. It issued a "Notice on Initiating Opinion Collection Work," setting up three methods for reporting and collecting opinions. Employees can provide anonymous feedback or reports through a suggestion box, email (email address: yijianxiang@zhongsheng.com.cn), or directly to the worker representative. If confidentiality is required, the worker representative will keep the information confidential. Once a report is received, management will take timely action to ensure that no whistleblower will suffer discrimination, unfair treatment, or retaliation, thereby protecting whistleblowers to the greatest extent.



BUSINESS INFORMATION SECURITY

Biosino strictly adheres to relevant laws, regulations, and GEM Listing Rules of the Stock Exchange, as well as the Company's internal "Articles of Association" and "Information Disclosure System." The Company has diligently fulfilled its information disclosure responsibilities as a listed Company. Biosino ensures that all publicly disclosed information is timely, fair, true, accurate, and complete, to guarantee that all investors have equal and timely access to relevant Company information. During the Reporting Period, the Company did not find any information that should have been disclosed but was not disclosed in a timely manner.

The governance of Biosino does not have significant differences from the requirements of the China Securities Regulatory Commission and the Hong Kong Stock Exchange. The Company will continue to consolidate and further improve its governance level, enhance corporate competitiveness, and thereby return better operating results to our investors.

Biosino places great emphasis on the protection of customers' trade secrets, data information, and personal privacy. Through strict internal control processes, we have achieved the security and controllability of information collection, processing, and transmission. Biosino strives to implement the security of business information in every aspect of serving our customers. We strictly comply with laws, regulations, policies, and industry standards related to customer privacy protection. New employees sign a confidentiality agreement upon joining the Company, agreeing to confidentiality obligations during and after their employment.

Biosino accepts audits from customers on the Company's data security, data center management, and general control processes to ensure risks are maintained at a controllable level. In response to cybersecurity issues, the Company has established complaint and reporting channels, allowing all employees to report through a suggestion box, email (email address: yijianxiang@zhongsheng.com.cn), or directly to the worker representative. During the reporting period, there were no significant cybersecurity incidents or commercial information leaks.

STAKEHOLDER IDENTIFICATION

It is confirmed that in combination with the Company's own business characteristics and drawing on the experience of its peers, the main stakeholders of Biosino include: shareholders and investors, customers, employees, the Board and management, suppliers and partners, regulators and the government, as well as local society, non-governmental organizations and the media. Biosino can fully respect the legitimate rights of stakeholders and actively cooperate with them on the basis of fairness, rationality and mutual benefit to jointly promote the sustainable and healthy development of the Company. This year, we communicated with stakeholders in many ways through online and offline meetings, face-to-face interviews, questionnaire, and other channels.

Stakeholders	Issues of Concern	communication Channels
Shareholders and Investors	■ Compliance operation ■ Information transparency ■ Return on investment ■ Improve product and service quality ■ Risk management ■ Corporate governance ■ Market position	■ General meeting of shareholders ■ Timely disclosure, on the information disclosure website ■ Roadshows and public events ■ Setup telephone, email and other communication channels
Customers	■ Stable relationship ■ Customer service quality ■ Protect customer privacy ■ Business integrity and ethics Health and safety	■ Service visit ■ Satisfaction survey and product training ■ Telephone ■ Wechat ■ Email
Employees	■ Development and training ■ Occupational health and safety ■ Compensation and benefits ■ Employee care ■ Employee communication	■ Satisfaction survey ■ Signing agreements ■ Hold meetings ■ Discussion ■ Organizing activities
the Board of Directors and Management	■ Compliance operation ■ Anti corruption ■ Talent retention ■ Enterprise sustainable development	■ Holding a meeting ■ Online communication
Suppliers and Partners	■ Fair bidding ■ Business ethics and reputation ■ Long term cooperative relationship	■ Supplier meetings ■ Field investigation ■ Signing contracts ■ Telephone ■ Wechat ■ Real-time email communication
Government and Regulators	■ Compliance with regulations ■ Policy implementation ■ Pay taxes ■ Responding to national strategies	■ Accept inspection and research ■ Fill out a form ■ Assist in review
NGO and Media	■ Give back to society ■ Environmental protection ■ Social welfare ■ Health and safety	■ Exchange, interview and contact ■ Community activities

Biosino is able to fully respect the legitimate rights and interests of stakeholders such as product users, creditors, suppliers, employees, and communities. We will actively cooperate with them on the basis of fairness, reciprocity, and compliance with laws and regulations, to promote the sustainable and healthy development of our Company.

MATERIALITY ASSESSMENT

In accordance with the "Environmental, Social, and Governance (ESG) Reporting Guide" of the Stock Exchange, and taking into account both internal and external stakeholders' assessment of potential issues listed, as well as the business attributes of Biosino, the Company identified 24 significant issues related to its business. It invited stakeholders such as employees, customers, suppliers, and Company executives to participate in both online and offline surveys to score and rank these potential significant issues. Finally, based on the survey results, the Company revised and supplemented the content of the significant issues and created a significance issue matrix.

Materiality assessment



Category	High Importance Issues	Medium Importance Issues
Corporate Governance	■ Risk Management ■ Corporate culture and Employee Relations Management ■ Business Information Security ■ The Importance of Bio Safety in the IVD Field ■ ESG Governance	■ Supply Chain ESG Management ■ Business Ethics and Anti-corruption ■ Internal Control and Supervision ■ Responsible Marketing
Product Innovation	■ Technology and Innovation ■ Product and Service Quality	■ Intellectual Property Protection
Green and Low-Carbon	■ Emissions Management ■ Resource Consumption Management	■ Energy Management ■ Environmental Management System ■ Climate Change Mitigation and Adaptation
Employee Development	■ Talent Development and Retention ■ Employee Rights and Benefits	■ Occupational Health and Safety ■ Diversity and Equality
Giving Back to Society		■ Health Promotion and Inclusivity ■ Industry Development and Win-win Cooperation ■ Community and Philanthropy

For ESG materiality issues, this report is based on the reporting principles of importance, quantification, balance and consistency. Major content changes have been reviewed and presented in the form of annual comparison for review by stakeholders.

Importance. When the issues related to ESG will have a significant impact on investors and other equity holders, they need to be disclosed in the report.

Quantification. Make the key performance indicators measurable so that the benefits of ESG management system can be evaluated and verified.

Balance. The ESG report presents the performance of the issuer in an impartial manner to avoid the possibility of improperly afecting the decision-making or judgment of the readers.

Consistency. This report adopts the same data disclosure method as in previous years, without comparing data from diferent years, and includes changes in statistical methods and key performance indicators.

PRODUCT RESEARCH AND DEVELOPMENT AND INNOVATION

HEALTHCARE INCLUSIVITY

Early Screening First

In September 2025, Zhongke Jinchen Biotechnology, a subsidiary of Biosino, officially launched its innovative multi-cancer early screening small panel “One Tube Safe” in Taiyuan, Shanxi Province. The technology achieves a breakthrough by using only one tube of peripheral blood to simultaneously screen for ten high-incidence cancer types, including lung, liver, colorectal, gastric and oesophageal cancers, with sensitivity and specificity both approaching 90% and tissue localisation accuracy reaching 85%. It offers an efficient, precise and cost-effective Chinese solution for large-scale population early screening.

On the same day, Biosino Medical Biotechnology (Shanxi) Co., Ltd. was officially established, marking a key step in the Group’s nationwide precision medicine rollout. Leveraging the parent Company’s five decades of in vitro diagnostic expertise and its self-constructed Chinese population methylation fingerprint database, this initiative aims to advance the “front-loading” of cancer prevention and treatment, effectively addressing the public’s difficulty in accessing early screening.

From technological R&D to regional deployment, from the laboratory to grassroots communities, Biosino is transforming advanced diagnostics into accessible healthcare services through evidence-based medicine. The Company ensures that precision early screening not only remains at the academic frontier but also takes root in Shanxi and radiates across the nation, fulfilling its corporate commitment to “beautifying life with technology”.

Research Ethics

The Company follows the ethical principles of the Declaration of Helsinki by the World Medical Association and the national requirements for the ethics of biomedical research involving humans. In the development process of in vitro diagnostic reagents, it strictly adheres to the "Regulations for the Registration and Record Management of In Vitro Diagnostic Reagents," "Quality Management Standards for Medical Device Clinical Trials," "Technical Guidelines for Clinical Research of In Vitro Diagnostic Reagents," and relevant laws and regulations to ensure our R&D activities are both innovative and responsible, prioritizing the rights, safety, and health of research subjects above scientific and social interests.

During clinical research, we consider the acquisition of trial samples and the risk of trial results to subjects, seeking ethical committee review to ensure that the trial does not expose subjects to unreasonable risks. Before the trial, clinical trial protocols, informed consent forms, and other relevant documents are submitted to the medical ethics committee of the hospital where the clinical trial responsible unit is located by the hospital's clinical trial management department, and clinical trials can only begin after obtaining approval from the ethics committee.

If it is objectively impossible to obtain informed consent from research subjects or the study uses patients' residual samples from routine diagnostic and treatment processes without any contact with the patients, posing virtually no risk to the subjects, exemption from informed consent may be granted after review and approval by the ethics committee.

Research testing results are only used for product registration applications, with no link between results and individual patient identity information, and no test reports sent to patients. There is no harm to the rights, safety, or privacy of research subjects.

Through these measures, our Company is committed to reflecting high ethical standards in the R&D process to protect the rights and welfare of participants while advancing medical science.

Responsible Marketing

The Company makes every effort to identify and reduce potential compliance risks caused by improper marketing practices, strictly adhering to the laws, regulations, and industry standards related to marketing in the operating locations. The Company regularly provides specialized training on responsible marketing to all employees related to marketing positions, including laws and regulations, internal rules and regulations, and product knowledge. Training is conducted both online and offline to help marketing personnel understand the group's regulations related to marketing, ensuring they promote and sell products and services reasonably and compliantly. A material review and supervision procedure has been established based on responsible marketing principles, with all marketing materials requiring approval from authorized Company personnel before release.

During the Reporting Period, based on internal compliance monitoring and to the best of the Group's knowledge, the Group was not subject to any material confirmed breach of laws and regulations relating to product and service information, labelling, and marketing communications (including advertising, promotion and sponsorship) in its principal operating locations.

TECHNOLOGY AND INNOVATION

The Company has established a project-centric performance evaluation system, shifting the focus of R&D center management from project process control to the initiation and acceptance of outcomes.

Since pioneering China's enzymatic mono and dual biochemical reagents, Biosino has been guided by the need to meet public welfare demands and taken it upon itself to promote the development of the national IVD industry. The Company emphasizes investment in technological R&D, actively carries out technological innovations, perfects the intellectual property protection system, fully leverages the advantages of its proprietary intellectual property, and insists on continuous independent innovation. It has established multiple research platforms, including enzymatic reaction systems, chemical reaction systems, reference materials, immunological detection methods, genetic diagnosis technologies, clinical rapid diagnosis, and flow cytometry. The Company boasts a 28 member R&D team, a 3,000 square meter R&D center, and advanced diagnostic equipment.

March

The Company obtained the CNAS medical reference laboratory accreditation, achieving mutual recognition of reference measurement results internationally, marking an upgrade in its calibration and testing capabilities.

April

The South Sichuan Institute of Translational Medicine and Biosino Precision Medicine jointly established a joint laboratory for the whole-process management of cancer, covering "prediction, early screening, treatment and rehabilitation", serving a population of 40 million in Yunnan, Guizhou, Sichuan and Chongqing.

September

The 4-laser 21-colour BioCyteX high-end flow cytometer obtained the medical device registration certificate from the National Medical Products Administration (Anhui Medical Device Registration No. 20252220150). As the first domestic four-laser flow cytometer product registered in China, it can simultaneously excite 21-colour fluorescence and acquire 24 parameters, meeting the demands of high-complexity immunophenotyping and minimal residual disease (MRD) monitoring, marking a key breakthrough for domestic flow cytometry.

September

Zhongke Jinchen launched the "One Tube Safe" multi-cancer early screening small panel in Shanxi. With only one tube of peripheral blood, it simultaneously screens ten high-incidence cancer types, with sensitivity and specificity both approaching 90% and tissue localisation accuracy reaching 85%. Relying on an independent Chinese population methylation database, it provides an efficient and precise solution for large-scale early screening.

December

The BOKE Group and Biosino strategic integration inaugural conference was held in Hainan. Under the theme "Dual-core Drive, Integration for the Future", both parties advanced supply chain and technology dual empowerment.



Product Innovation

The Pathfast fully automated point-of-care cardiac marker detector made its debut at the China Heart Congress (CHC 2025). The system supports whole-blood loading for high-sensitivity cardiac troponin I (hs-cTnI) testing, with six interchangeable channels and the ability to complete six tests in 17 minutes. It offers rapid, accurate and flexible performance, providing robust support for the early diagnosis of cardiac diseases.

The Total Bile Acid Quality Control product obtained a Class II medical device registration certificate from the Beijing Medical Products Administration (Beijing Medical Device Registration No. 20252400830), further strengthening the Company's biochemical testing quality control product line.

The AutoProSample A960 Fully Automated Flow Cytometry Workstation was showcased at MEDICA 2025. In combination with the BioCyte X flow cytometer, it addresses the challenges of automation, standardisation and intelligence in pre-analytical flow cytometry sample processing.


The "Nine-Steam-Nine-Sun Polygoni Rhizoma" (a medicinal and edible product) was presented on the international stage for the first time at MEDICA 2025. Originating from Mount Jiuhua in Anhui, the product integrates both medicinal value and health benefits, embodying the wellness wisdom of traditional Chinese medicine and facilitating the global reach of Chinese medicinal culture.

Intellectual Property Protection

The Company continues to increase R&D investment, continuously improves technology and production processes, focuses on product quality system construction, is committed to extending product lifecycles, reducing costs, and providing safer and more effective products and services. To protect related intellectual property, the Company's R&D personnel write patent applications for the products developed.

On the path of insisting on independent innovation, Biosino continues to deepen product reforms, focusing on strengthening the protection and application of intellectual property, accelerating product innovation, and promoting outcome transformation. To date, the Company has obtained 140 authorized patents, including 82 invention patents, 43 utility model patents, and 15 design patents; obtained 31 software copyrights, a total of 38 trademarks, and has published 48 papers.

Access to intellectual property (million)



Registered Products

The group Company currently holds a total of 281 medical device registration certificates. In 2026, the Company will carry out the registration of additional new products to maintain its leading position in the registration certificates. The Company's products mainly cover 16 categories of biochemical tests, including liver function, kidney function, blood lipids, cardiovascular, diabetes, rheumatism and so on.

■ Number of Medical Device product Registrations by Enterprises (within validity period)


BIOSINO Biotech Co., Ltd. Registered Quantity

281

BIOSINO Biotech Co., Ltd. Enterprise Ranking Tied

Leading position

■ The classification and distribution map of biochemical diagnostic reagents, total number: 281 (Category name, percentage in the total)



PRODUCT AND SERVICE QUALITY

As one of the largest industrial bases of medical biochemical diagnostic reagents in China, Biosino adopts internationally advanced management models to realize advanced production processes such as microcomputer networking and automatic connection, and the production environment is fully enclosed, clean and automatic temperature control. At the same time, in strict accordance with the standard requirements of IS0 13485:2016, quality management personnel, quality control personnel and production operators with strong sense of responsibility and excellent technology are equipped to monitor the whole production process. A perfect and strict quality control system is established. Quality control is carried out in the production process to ensure the repeatability and stability within and between batches of products; By participating in the inter-laboratory quality assessment activities of the National Health Commission of the People's Republic of China and Beijing authorities, the accuracy of the products meets or exceeds the standard requirements. During the Reporting Period, the Company did not return products for safety and health reasons. Because the products sold by the Company do not reach consumers directly, it does not involve the protection of consumer data or privacy policies.

During the Reporting Period, the Company had no products returned for safety and health reasons; since the Company's products did not reach consumers directly, there were also no issues related to the protection of consumer data and privacy policies.

In order to promote partners to continuously improve their quality management level, the quality manual formulated in 2009 is revised and improved annually according to the requirements of laws, regulations and quality management system.

■ **Obtained inter-laboratory quality assessment certificates from the National Health Commission Clinical Inspection Center.**



Quality Management Commitment

The highest rank supervisor of the Company's quality management system is the president. In order to ensure the establishment, implementation and effectiveness of the Company's quality management system, the Company promises:

- Establish the guiding ideology of "focusing on customers" among all employees and translate it into the specific requirements of the Company;
- Formulate quality policy;
- Formulate quality objectives;
- Conduct management review regularly;
- Ensure the availability of resources and continuously improve the effectiveness of the quality management system.

Quality Management System


As a manufacturer of IVD, Biosino establishes, implements and maintains a quality management system and maintains its effectiveness in accordance with the requirements of ISO 13485:2016"Medical Device Quality Management system Requirements for Regulations"and"Medical Device Production Quality Management specifications".

Quality policy

High quality efficient innovative premium reagent products accurate, stable, detect life functions

As a manufacturer of in vitro diagnostic reagents, Biosino determines the required processes, including those related to management responsibilities, resource management, product realization, measurement analysis and improvement; the risk management control procedure is established and implemented to manage the process throughout the product life cycle. The sequence and interaction of the processes are clearly defined.

Document structure of quality management system



Description of quality policy, quality objectives, processes required by the quality management system and their interactions

The ways and steps of implementing quality activities and the description of the process

Guiding operation documents and record forms

In 2005, Biosino was the first company in China to establish a microcomputer-managed automatic production line and constructed a new plant in strict accordance with GMP standards. At the same time, in order to ensure the stability and consistency of the product quality, the Company is equipped with internationally leading fully automatic biochemical analyzers, including those from Hitachi, Beckman, and Abbott. It has automatic filling and plugging linkage machine, three head screw sub packer, freeze dryer and other automatic production equipment. Pure water treatment system and ultra pure water device are introduced. By combining advanced production technology and management means, Biosino provides strong technical support for the all-round compliance of clinical diagnostic reagents of Biosino.

Safety and Quality System Certification

Biosino has obtained a series of safety and quality management system certification, laboratory accreditation and other certificates:

- Three level review certificate of enterprise safety production standardization issued by the state Emergency Management Bureau;





- ISO13485:2016 Medical Device Quality Management system Certification



- ISO / IEC 17025:2017 General requirements for the competence of the laboratories in testing and calibration.



Since its establishment in 1988, Biosino has placed great emphasis on technology research and development and innovation, continuously improving its management and technical capabilities, and strictly controlling product quality, always striving for innovation and excellence. Biosino has once again successfully passed the qualification review and regular review of the China National Accreditation service for Conformity Assessment (CNAs), indicating that its calibration and testing services have been upgraded and its management and technical capabilities have been recognized by the state, demonstrating the Company's comprehensive strength in the industry.

Service Guarantee

Biosino pursues the purpose of "technical service first", and has set up a technical service department to appoint high-quality talents majoring in inspection, pharmacy, medicine and marketing to conduct regular market patrol research and user follow-up. By holding training courses, holding academic exchanges, regularly publishing the bulletin of laboratory medicine technology, and combining with online interaction, we can provide users with professional technical support and services, and solve various difficult problems in product application on site. We also endeavour to provide customers with the best service at the first time.

The Company has established and implemented the customer feedback management procedure to standardize the customer complaint handling process in accordance with applicable laws and regulations, clarify the responsibilities of each department, and clarify the timeliness and effectiveness of customer complaint handling. The quality management department shall keep complaint handling records. The record includes:

- Receiving and recording information;
- Evaluating the information to determine whether the feedback constitutes a complaint;
- Investigating complaints;
- Determining whether information needs to be reported to the appropriate regulatory authorities;
- Disposal of products related to complaints;
- Determining whether corrective actions need to be initiated or not.

In 2025, the Group recorded 0 product quality complaints. There were 6 cases of returns due to product packaging damage and leakage in individual products, and the returned products were disposed of as scrap.

The Company has simultaneously established and implemented the control procedure for adverse event monitoring and re-evaluation of medical devices, carried out adverse event monitoring and re-evaluation, and reported major quality accidents or advisory notices to relevant regulatory authorities. The quality management department shall keep records of reports to the regulatory authority.

In addition, the Company has established and implemented the product monitoring and measurement control procedure to monitor and measure the characteristics of products to verify that the product requirements are met. For the control of nonconforming products, the Company has established and implemented the nonconforming product control procedure to ensure the identification and control of nonconforming products to prevent unexpected use or delivery.



GREEN AND LOW-CARBON DEVELOPMENT

Biosino attaches great importance to environmental protection, emphasizes the importance of environmental protection to corporate social responsibility and sustainable development, and actively promotes the construction and implementation of environmental protection management system. Biosino attaches great importance to environmental protection, emphasizes the importance of environmental protection to corporate social responsibility and sustainable development, and actively promotes the construction and implementation of environmental protection management system.

ENVIRONMENTAL PROTECTION POLICIES AND OBJECTIVES

From the strategic perspective of environmental and social sustainable development, Biosino strictly controls pollution, promotes energy conservation and emission reduction, protects the ecological environment, and strives to create an environment-friendly business community. During project screening, the Company focuses on its potential impact on the environment, attaches great importance to environmental protection, ensures the environmental impact compliance and compliance of Biosino's business activities, actively enables the wide application of advanced environmental technology in the Company's business activities, reduces resource consumption, and advocates the attention of all stakeholders to environmental protection.

During the Reporting Period, the Company and relevant departments carried out full coverage inspection on the environmental management status of all holding subsidiaries, promoted the improvement of environmental management of holding subsidiaries, and completed the construction and implementation of management system within a time limit, so as to effectively ensure the sustainable development of the enterprise. During the Reporting Period, Biosino, its subsidiaries and joint-stock enterprises did not have any environmental pollution incidents.

Our Goals

Greenhouse Gas Reduction Targets	Energy Consumption Reduction Goal	Water Resource Conservation Goal	Waste Management Goals
Achieve peak carbon emissions by 2028, and carbon neutrality by 2050.	Based on the year 2021, reduce energy consumption intensity by 20% by 2030.	Based on the year 2021' reduce water use intensity by 10% by 2030.	Prefer zero landfill for hazardous waste disposal, reducing the long-term environmental impact of pollutant disposal, with no increase in hazardous waste intensity by 2030. Implement projects to reduce the amount of nonhazardous waste, aiming to reduce the intensity of nonhazardous waste by 10% (tons per 10,000 RMB) by 2030.
2028 2050	20%	10%	

ADDRESSING CLIMATE CHANGE

As the first enterprise in the IVD field to propose a "dual carbon" goal, Biosino actively responds to the climate change initiative of the Paris Agreement and China's "dual carbon" strategic objectives. The Company identifies climate change-related risks and opportunities and refers to the International Sustainability Standards Board (ISSB)'s "IFRS Sustainability Disclosure Standard S2-Climate-related Disclosures (Exposure Draft)" to disclose relevant information about the Company's climate change risk management.

Governance

The Company's board of directors and ESG committee are responsible for regularly reviewing the execution of climate change-related matters in the ESG report, supervising the implementation of the "carbon reduction" targets, promoting energy structure adjustment, improving equipment energy efficiency, advocating for office energy saving, and collaborating with suppliers to reduce carbon emissions in the supply chain.

Strategy

The Company integrates climate change risks into its comprehensive risk management framework, including the identification, assessment, and management of climate change risks. Based on scenario analysis of ISSB-2, the Company combines industry characteristics, localised operation policy orientation and geographical features, and historical records of extreme weather to identify a significant list of climate risks related to the Company, promoting the implementation of climate change risk management across the entire value chain. In the short term, the Company will conduct risk assessments and financial forecasts; in the medium term, it will develop plans that align with policy trends, market development, and customer demands; in the long term, it aims to achieve the goal of carbon neutrality.

Significant Climate Change Risks			Relevance Explanation
Physical Risks	Chronic Risks	Increase in average temperature	The production workshops for reagents have high temperature requirements. In the scenario of global warming, the Company anticipates an increase in energy consumption to maintain normal production operations, further increasing operational costs. Additionally, a rise in temperature leading to more frequent hot weather exacerbates health risks for employees.
	Acute Risks	Increased frequency of extreme weather events	Global warming causes instability in the climate system, making extreme weather events more frequent and severe, which poses challenges to the Company's operational stability. Moreover, the costs associated with addressing these extreme weather events contribute to increased operational costs.
Transition Risks	Policy and Legal Risks	Requirements and regulations for existing products and services	Governments are improving carbon emissions trading and management systems to meet the goals of the Paris Agreement. This could lead to increased costs of greenhouse gas emissions through carbon taxes or higher fuel and electricity prices. As more industries are included in the carbon emissions trading system, the Company may face higher operational costs.
	Technological Risks	Upfront costs of transitioning to low-emission technologies	In response to government "dual carbon" policies and stakeholder expectations, the Company will advance research in low-carbon technologies and optimize energy structure to reduce carbon emissions and improve energy eficiency, which will result in increased operational costs.
	Market Risks	Rise in raw material costs	Climate change can affect the quantity and stability of raw materials, with a reduction in supply leading to increased costs.
	Reputational Risks	Stakeholders' growing concern over negative feedback	Global warming and the accompanying impacts of climate change have attracted increasing attention from corporate stakeholders. Therefore, they have higher expectations for the actions companies take in addressing these challenges.

Risk Management

To proactively address the identified climate change risks, our Company has developed "adaptation" and "mitigation" strategies to manage climate change risks effectively.

Adaptation Strategies	Our Company enhances its response to new government policies by regularly inspecting the electrical systems, steam systems, drainage systems, and electrical instruments, as well as conducting regular inspections of outdoor factory facilities. Continuous investment in equipment renewal and optimization is also a priority.
Mitigation Strategies	Our Company continuously updates refrigeration equipment, including compressors and condensers, by establishing smart distribution rooms and steam automatic operation and maintenance systems. This approach not only saves on electricity and steam costs but also achieves energy savings and emission reduction.

Goals

Our Company has set strategic "dual carbon" goals to achieve carbon peak by 2028 and carbon neutrality by 2050. In terms of supply chain management, suppliers of enzymes, antigens antibodies, packaging materials, and cold chain logistics have been invited to participate in ESG training and audits. We require Class A logistics suppliers to provide carbon emission data and information. The supplier self-assessment process now includes the requirement to conduct carbon assessments. Since its commissioning, the smart power distribution room at the Company headquarters has been operating safely and stably, saving approximately 200,000 yuan in electricity costs annually.

The steam automated operation and maintenance system at the headquarters has also operated securely and smoothly since its launch, reducing expenses by 150,000 yuan in 2025 compared to the previous year. Additionally, the Company's HR department has intensified efforts in localized recruitment to address local employment needs. With employees now working closer to home, low-carbon commuting has been promoted. By consolidating two shuttle buses into one, energy consumption has been further reduced.

Through these practical actions, we are gradually progressing towards our "dual carbon" goals.

Biosino's "Dual Carbon" Goals:

Achieve carbon peak by 2028 and carbon neutrality by 2050.

Training

Employee participation is key to achieving our emission reduction targets and implementing our climate change adaptation plan. The Company proactively offers training courses, lectures, and other internal communication channels to raise their awareness in addressing climate change. Biosino invites ESG experts to conduct ESG training for the Company's supplier representatives and leaders, Biosino executives, and heads of various departments. The training content includes the development history of ESG concepts, international and domestic policy trends, and corporate case studies in the ESG field.

Performance

In 2025, Biosino relied on the GHG Protocol: Corporate Accounting and Reporting Standard (2004), with reference to ISO 14064-1:2018 and the Guidelines for Accounting and Reporting of Greenhouse Gas Emissions for Enterprises in Other Industrial Sectors, and in accordance with the relevant requirements of the Ministry of Ecology and Environment of the People's Republic of China, adopted the emission factor method to account for the Company's Scope 1 and Scope 2 greenhouse gas emissions.

The Company's direct emissions (Scope 1) mainly come from the operation of owned vehicles and the escape of refrigerants; indirect emissions (Scope 2) mainly come from electricity and steam used in factories and office buildings.

1 The Carbon Emissions from the Operation of Self-owned Vehicles

The formula for calculating the carbon emissions from the operation of self-owned vehicles is:

Emissions = Gasoline Consumption (liters) × Regional Power Grid Emission Factor ($kgCO_2e/L$).

In 2025, the gasoline consumption of the self-owned vehicles of Biosino (including all its branches) was 52,300 L. According to the data queried from the IPCC emission factor database, the carbon emission factor of gasoline during vehicle driving is 2.31 $kgCO_2e/L$. Calculated according to the formula, the annual carbon emissions of the self-owned vehicles amount to 120.81 tCO_2e.

2 The Carbon Emissions from the Escape of Refrigerants

The formula for calculating the carbon emissions from the escape of refrigerants is:

Refrigerant escape amount × Global Warming Potential (GWP).

In 2025, the refrigerant escape amount of Biosino (including all its branches) was 30 kg, among which the amount of R507 refrigerant was 10 kg and the amount of R22 refrigerant was 20 kg. According to the data queried from the IPCC emission factor database, the Global Warming Potential (GWP) of R507 is 3,985, and the Global Warming Potential (GWP) of R22 is 1,810. Therefore: Carbon Emissions = (10×3,985 + 20×1,810) kg CO_2e = 76.05 tCO_2e.

3 The Carbon Emissions from Purchased Electricity

The formula for calculating the carbon emissions from purchased electricity is:

Emissions = Purchased electricity volume (kWh) × Regional power grid emission factor ($kgCO_2e$/kWh).

Among them, the provincial emission factor adopts the latest provincial or regional power grid emission factor released by the Ministry of Ecology and Environment of China.

In 2025, a total of 1,210,000 kWh of electricity was purchased from State Grid Beijing Changping Power Company (the agreement contract is presented in the attachment). Biosino Jinyu does not have the latest electricity purchase contract document, but since Biosino Jinyu and Biosino are both in Changping District, Beijing, it is reasonably inferred Bionsino Jinyu's electricity comes from the Beijing power grid. The Bionsino Jinyu's electricity consumption in 2025 was 418,600 kWh. The emission factor of the Beijing power grid is 0.558 kg CO_2e/kWh.

In 2025, Biosino Anhui purchased a total of 31,939 kWh of electricity from State Grid Anhui Power Grid (the agreement contract is presented in the attachment). The emission factor of the Anhui power grid is 0.6782 kg CO_2e/kWh.

In 2025, Biosino Suzhou does not have the latest electricity purchase contract document, but since the it is in Suzhou, it is reasonably inferred that its electricity comes from the Jiangsu power grid. Biosino Suzhou's electricity consumption in 2025 was 60,000 kWh. The emission factor of the Jiangsu power grid is 0.5978 kg CO_2e/kWh.

Table: Carbon Emissions of Biosino in 2025- Overview

	Purchased Electricity Volume（kWh）	Emission Factor (kg CO_2e /kWh）	Emission （t CO_2e）
Biosino*	1,210,000	0.558	675.18
Biosino Jinyu	418,600	0.558	233.58
Biosino Anhui	31,939	0.6782	21.66
Biosino Suzhou	95,000	0.5978	56.79
	Total		987.21

4 The Carbon Emissions from the Purchased Steam

The greenhouse gas (“GHG”) emissions arising from purchased steam are calculated using the following formula:

GHG Emissions = Steam Consumption × Steam Delivered Energy × Natural Gas Emission Factor ÷ Boiler Efficiency at the Steam Supply End.

Among these parameters, the steam delivered energy is determined based on the enthalpy value of steam. The natural gas emission factor is calculated on the basis of fuel combustion energy, and the boiler efficiency is used to convert steam-end energy into fuel-end energy.

The steam delivered energy is derived from the national standard Steam Enthalpy Tables. The purchased steam is low-pressure steam, with an energy content of approximately 0.0028 TJ per tonne. The carbon emission factor for natural gas combustion is sourced from the National Greenhouse Gas Emission Factor Database, which is 56.1 tCO_2e/TJ.

As Beijing District Heating Company Limited adopts gas-fired boilers for steam supply and the actual annual boiler efficiency data was not available, the boiler efficiency at the steam supply end is estimated at 0.90, representing the commonly adopted efficiency level of gas-fired boilers.

In 2025, Biosino purchased a total of 360 tonnes of steam from Beijing District Heating Company Limited. Based on the above formula, the total GHG emissions attributable to purchased steam for the year are calculated as follows:

360 t × 0.0028 TJ/t × 56.1 tCO_2e/TJ ÷ 0.90 ≈ 62.83 tCO_2e.

Greenhouse Gas Emission summary for Biosino During the Reporting period

■ Scope 1: The direct greenhouse gas emissions generated by emission sources owned or controlled by Biosino and its subsidiaries amounted to 196.86 tCO_2e, primarily including emissions from the operation of owned vehicles and refrigerant leakage.

■ Scope 2: The indirect greenhouse gas emissions generated from the electricity and steam purchased by Biosino and its subsidiaries amounted to 1,050.04 tCO_2e, primarily including emissions from electricity and steam usage in factories and office buildings.

LOW-CARBON OFFICE

Since October 2022, Biosino has vigorously advocated for paperless office practices since adopting the OA (Office Automation) system, significantly reducing tree felling and carbon emissions while also enhancing information management efficiency, reducing office costs, and facilitating daily work for employees. We have integrated various work processes, including instant messaging, email, announcements and notifications, attendance management, administrative office work, process center, public filing cabinets, and mobile office functionalities. Additionally, all tasks, including those related to human resources modules and financial approvals, are processed through OA's online approval workflows. In 2025, the process center approved over 20,000 workflows, resulting in an approximate carbon reduction of 5 tons of CO_2e,.

Approval Process Over
20000
entries

Greenhouse Gas Carbon Reduction
5
tCO_2

Establishment of the "Employee Low-Carbon Behavior Code"

Biosino, based on the "Low Carbon Office Evaluation" group standard, has reviewed its office carbon footprint, established, and implemented the "Employee Low-Carbon Behavior Code" to regulate employee behaviors towards energy saving and improved resource utilization efficiency.

Smart Distribution Rooms

The smart power distribution rooms retrofitted by the company headquarters in 2023 has been operating efficiently in 2025, achieving annual savings of approximately 200,000 yuan in electricity costs, 250,000 kWh of energy consumption, and a reduction of 140 tons of CO_2e, emissions.

EMISSION MANAGEMENT, THE UTILIZATION OF RESOURCE AND ENERGY

Emission Management

As the Company is mainly engaged in the production, sales and distribution of IVD reagent products, the business does not produce or discharge nitrogen oxides, sulfur oxides and other pollutants regulated by Chinese national laws and regulations. The Company entrusts a third-party organization to uniformly dispose of the generated hazardous waste on a regular basis. On the premise of ensuring the safety of hazardous waste storage, transportation and disposal, Biosino realizes the reduction of hazardous waste by standardizing the behavior of employees and raw material substitution. In addition, emissions are reduced through the design of products that reduce the generation of waste liquid.

Pollutant Emission Classification:

■Sewage: it is composed of industrial sewage and domestic sewage. Main types of pollutants: ammonia nitrogen, suspended solids and oils.
■Atmospheric emission: vehicle exhaust, etc.
■Solid waste: it consists of hazardous waste and general waste. Hazardous wastes include chemical raw materials used in the production process, acids, alcohols, etc. and medical wastes generated in the laboratory. General wastes include recyclable wastes, such as packaging materials and domestic garbage generated by office.

Biosino strictly abides by the relevant laws and regulations and relevant standards for the discharge of waste gas, wastewater and waste in the place of operation.

Measures to control pollutant emission:

■ After the sewage treatment and pretreatment and it meets the standard, it is discharged into the back-end secondary sewage treatment plant or the municipal sewage pipe network.

■ To control vehicle exhaust discharge, only vehicles that comply with the national standards are used in accordance with the regulations.

■ Each holding subsidiary should carry out the final compliant disposal through a professional organization with disposal qualification approved by the local environmental protection bureau, and carry out incineration, landfill or reprocessing and utilization in accordance with the regulations.

Resource use, energy consumption and investment in environmental protection facilities

Our Company and its subsidiaries actively practice energy conservation and emission reduction by rationally utilizing water and electricity resources, reducing energy consumption to lower operational costs and protect the environment. During the reporting period, we continuously strengthened our investment in environmental protection, optimized production processes, and improved equipment efficiency, committing to environmental protection and energy saving. The environmental protection facilities established by the Company are operating normally, ensuring that wastewater and exhaust gas treatment meet standards and that hazardous waste is disposed of in accordance with regulations.
The Company's water supply primarily comes from municipal water services, mainly used for domestic water, air conditioning cooling water, and cleaning in research and development production. Biosino has established a corresponding water-saving system to ensure standardized water use in production and daily life, avoiding unnecessary waste of water resources.

To reduce water consumption, the Company has taken the following specific measures:
• Water Resource Assessment and Monitoring: The Company regularly assesses and monitors water resource usage to promptly identify any abnormal water usage situations and take measures to ensure continuous improvement in water use efficiency.
• Summer Central Air Conditioning System: Our Company's air conditioning cooling system uses water recycling technology, greatly reducing the consumption of cooling water.
• Application of Water-Saving Devices: The Company has installed water-saving devices such as efficient faucets at all water points, effectively reducing the waste of domestic water. In addition, the Company uses a single piping system for heating and cooling, switching between summer and winter seasons through valves, to realize the recycling of water for heating and cooling, effectively saving water.
• Regular Maintenance: To ensure the efficient operation of the water system and reduce the loss of water resources, the Company regularly inspects and maintains water facilities and pipelines. By promptly identifying and repairing issues such as leaks and drips, we minimize water loss.

	Unit	2025
Use of water resources	cubic meter	15,084
Power consumption	kWh	1,720,539
Steam	ton	360
Solid waste	ton	3.98
Hazardous waste	ton	5.15

* Due to the diversity of product models, it is impossible to individually account for each product's energy and water consumption, making it dificult to calculate the specific energy and water consumption density of each product.

Use of packaging materials

In 2025, Biosino utilized various types of packaging materials for its finished products, primarily consisting of rubber, glass, plastic, and paper products. The consumption details include 55.5 tons of glass bottles, 35.0 tons of plastic bottles, 0.8 tons of rubber stoppers, 2.0 tons of aluminum caps, 13.2 tons of packaging boxes, 1.5 tons of A4 paper, 2.4 tons of labels, 15.4 tons of paper ice boxes, 0.3 tons of plastic bags, 12.5 tons of cardboard boxes, and 7.0 tons of foam boxes.

TALENT DEVELOPMENT

CORPORATE CULTURE AND HUMAN RESOURCES MANAGEMENT IDEOLOGY

From the beginning, Biosino has accumulated profound cultural heritage. It has built a career platform for employees through various institutional arrangements and organizational construction; And enter a cultural atmosphere at high speed through various exciting or warm activities.

Corporate Development Strategy

Integrated Core with Dual Wings, Dual-Drive, and Triple Chain Linkage

- Development Core: BIOSINO Technology Achievement Transformation Center
- Dual Wings: Transformation of Sci - tech Achievements and innovation in Service Industry Models.
- Transformation and Incubation of Hardcore Sci-tech Products: Precision, Medicine, High-end Equipment, Biotechnology, etc. Innovation and improvement of medical quality and service levels: Innovative Clinical Medical. Techniques, Medical Information technology, Service Process Reengineering, etc.
- Innovation Chain: Sci-tech Products + Innovative Services
- Industrial Chain: development around the Core Industry's Upstream and Downstream + Creation of an Ecosystem of Sci-tech Companies
- Capital Chain Supporting Special Venture Capital + M&A Funds

Corporate Talent Management Philosophy

Believe in the Future, Embrace Change, Transform Ourselves, Create Value

- Cultivate an executive team with passion, responsibility. Business acumen, and good management skills.
- Emphasize, performance orientation, inspire innovation, allow for mobility of managers and employees alike.
- Establish an evaluation system based on value creation and set up a mechanism for sharing corporate benefits with all employees.

Corporate Product Philosophy

Deliver high-quality, efficient, and innovative reagent products, ensuring accuracy, stability, and life function measurement

- Clarify research and development directions, enhance R&D efficiency
- Continuously optimize costs, capture market share.
- Strictly control product quality, build market competitiveness.

TALENT TRAINING AND RETENTION

Our Employees

Biosino has perfect system and standardized management, adheres to the principle of "respecting talents, trusting talents and understanding talents", creates a stage and opportunity for employees development, encourages employees to display their talents, makes the enterprise develop and grow by giving full play to employees talents, and reflects employees' own value through the development and growth of the enterprise.

Relevant employment systems include employee handbook, attendance and leave management system, salary management system of Biosino, performance appraisal management measures, probation management measures, employee transfer and promotion management measures, management measures for managers, welfare payment measures, harmony fund management measures, honor award regulations and regulations on the administration of labor insurance payment guarantee the rights and interests of employees, create fair and equal work opportunities for employees, provide rich welfare benefits, and provide protection for their career planning.

Biosino establishes and implements a sound salary incentive system, determines the post salary of personnel through different positions and ranks, establishes the salary system of R&D technicians, functional departments and sales personnel, establishes a reasonable rising channel, gives full play to the incentive role of salary, selects and reserves excellent talents according to the management personnel assessment methods and personnel promotion management methods, and establishes a talent reserve mechanism. Biosino abides by the provisions of the labour law, works within 8 hours a day, implements the two-day rest system, and provides annual leaves, marriage leaves, parental leaves and other legal holidays. The relevant subsidies include health care expenses, fever subsidies, professional title subsidies, age subsidies, cold storage subsidies, etc. The Company provides employees with equal opportunities for recruitment and promotion. At the same time, it has a complete set of management systems and regulations, which are strictly implemented.

Business centers

Center	Biosino	Biosino Anhui	Biosino Jinyu	Biosino Suzhou
Executives	7	1	4	2
Marketing center	76	1	13	29
R&D center	28	0	18	28
Manufacturing center	51	0	45	29
Management support center and Others	38	3	8	9
Office of Management and Operations	2	9	0	7
Total	202	14	88	104

Education

Educationn Level	Biosino	Biosino Anhui	Biosino Jinyu	Biosino Suzhou
PhD	2	0	2	4
Master's	30	0	8	12
Bachelor's	79	3	18	56
Associate Degree and below	91	11	60	32
Total	202	14	88	104

Title

Professional Title	Biosino	Biosino Anhui	Biosino Jinyu	Biosino Suzhou
Senior	11	0	1	2
Intermediate	36	2	8	13
Junior	42	3	3	57
None	113	9	76	32
Total	202	14	88	104

Age

Age Group	Biosino	Biosino Anhui	Biosino Jinyu	Biosino Suzhou
20-30 years old	26	5	9	18
31-40 years old	82	7	15	59
41-50 years old	70	2	44	26
51-60 years old	24	0	20	1
Total	202	14	88	104


Gender

Gender	Biosino	Biosino Anhui	Biosino Jinyu	Biosino Suzhou
Male	119	4	32	67
Female	83	10	56	37
Total	202	14	88	104


Disclosure of Employee Onboarding and Turnover Rates

The Company provides equal opportunities for onboarding and promotion for each employee, and has a well-enforced management system and regulations in place. Last year, Biosino adjusted its organizational structure, strengthened performance evaluations and personnel management, and reinforced an internal merit-based system. This system, through evaluations, eliminated the last unfit personnel element, optimized the personnel structure, and improved staff efficiency, leading to some departures. Additionally, there were employees who left for personal reasons, including not adapting to new positions after job changes, relocating to places far from the Company, and seeking other personal development opportunities.


Employee Turnover Rate and Entry Rate by Gender




Employee Turnover Rate and Entry Rate by Age Group




Employee Turnover Rate and Entry Rate by Center



Employment Type



Employee Turnover Rate and Entry Rate by Region



Development and Training

The Company consistently adheres to the training policy of "synchronizing professional and comprehensive development," which means that it cultivates both expert technical talent and well-rounded management talent. We follow the principle of "primarily internal training with supplementary external training," establishes a comprehensive training system for all employees, and implements a tiered training management model. Based on the Company's production operations and long-term development needs, annual training plans and medium- to long-term development strategies are formulated. The Company actively creates favorable learning and training conditions, providing employees with organized training to fully tap into their potential and promote their growth. We offer abundant career advancement opportunities and pathways, ensuring that employees have ample and comprehensive professional development.

The Company offers seven types of training: senior management training, middle management training, marketing training, professional technical training, professional skill training, general training for all employees, and new employee training. Training is conducted at three levels: Company, department, and team. An in-depth training needs analysis is conducted for various types of training to enhance the relevance of the training content, strengthen the follow-up assessment and evaluation of the trainees, apply what is learned, develop comprehensively, and improve the overall quality and capability of the employees through various training programs.

In 2025, the Company's quality management system, safety production system, and other training management systems operated well. There were 43 sessions on the dissemination of laws and regulations related to the production and operation of medical devices, 27 sessions of new employee training, 73 sessions of medical device operation system and production management system training, and more than 33 training sessions on fire protection, occupational health, work safety, biosafety, work safety management, intellectual property rights, and corporate law, etc.

Safety training



Operational training



Regulatory training



Sales training



- **Employee Training Coverage: 100%**



2025 Training Overview

Training Situation by Gender

Gender	Total Trainees	Percentage	Total Training Hours
Male	1,118	51.33%	820
Female	1,060	48.67%	1190
Total	2,178	100%	2010

Training Situation by Job Level

Job Level	Total Trainees	Percentage	Total Training Hours
Manager	280	12.86%	470
Staf	2,308	87.14%	1,540
Total	2,713	100%	1,754

Average Training Hours Per Employee

Gender	Average Hours per Person
Male	3.7
Female	6.4

Job Level	Average Hours per Person
Manager	4.8
Staff	5.3

The Company strictly implements and enforces the provisions of laws and regulations such as the "Labor Law of the People's Republic of China" and the "Labor Contract Law of the People's Republic of China," eliminating the employment of child labor and forced labor. Through regular employee training and a robust internal reporting mechanism, we ensure the complete eradication of employing child labor and forced labor in our business operations. In the recruitment process, we adhere to China's employment laws and regulations, uphold the principles of fairness and equality, and provide equal employment opportunities to all candidates. For behaviors that violate our policies, we will take the necessary disciplinary actions.

During the reporting period, there were no incidents of forced labor or employment of child labor.

Assessment and incentive

Biosino has formed a performance appraisal system based on KPI and balanced scorecard. Based on the post responsibilities of senior managers, the Company sets assessment indicators according to the Company's strategic objectives and budget decomposition at the beginning of each year, signs performance assessment letters and conducts performance assessment level by level. By the end of the year, their salaries are evaluated against their performance indicators, effectively implementing the performance evaluation standards and assessment procedures of senior managers. The Company also makes corresponding amendments and improvements according to the implementation.

At the same time, Biosino has established a targeted and operational evaluation and incentive mechanism at all levels, so as to further improve the corporate governance structure and all staff incentive mechanism, fully mobilize the enthusiasm of management and key employees, effectively combine the interests of shareholders, the Company and the personal interests of operators, and make all shareholders pay attention to the long-term development of the Company.

Biosino has established an internal control system, and the effectiveness and rationality of the system are supervised and evaluated through internal audit. The effective internal control system ensures the effective implementation of applicable laws and internal systems, effectively reduces the risk of corruption and violation, and improves the operation ability of the Company.

Biosino has issued additional domestic shares to key employees, further strengthened the incentive mechanism for senior managers and key personnel, and promoted the long-term and stable development of the Company.

OCCUPATIONAL HEALTH AND SAFETY

The Company places a high emphasis on the occupational health of its employees, aiming to prevent occupational hazards to health. In accordance with regulatory requirements, the Company organizes occupational health examinations for relevant personnel and has established a dedicated Occupational Health Committee and working group. Occupational health and safety education and publicity columns have been set up to disseminate regulations and system requirements, enhancing the protection of employee occupational health. Labor protection supplies are provided and regularly replaced to ensure their effectiveness and safety. In terms of occupational health management, the Company has achieved annual detection of occupational hazard factors and a triennial evaluation; employees in positions involving occupational hazards are informed in writing about potential occupational health risks at the time of signing the labor contract; a personalized occupational health surveillance record is established for each employee involved in occupational hazards; pre-employment, post-employment, and regular on-the-job occupational health examinations are conducted to track employees' health status, and employees found to have occupational contraindications through medical examinations are reassigned to prevent the occurrence of occupational diseases.

Since initiating its work on achieving standards in production safety in 2014, the Company has established a leadership group for production safety, an occupational health leadership group, a biosafety committee, and a leadership team. It was awarded the "National Second-Level Standard Enterprise for Safety Production" in 2014, and achieved the "Third-Level Standard Enterprise for Safety Production" and the "Beijing Municipal Occupational Health Infrastructure Standard Unit" in 2021. The Company supervises and manages all aspects of work related to safety production, biosafety, and occupational health in accordance with regulatory requirements in both production and business operations.

To establish biosafety protection procedures and strengthen the biosafety management of laboratories and production workshops to protect the health of laboratory and production workshop workers and ensure the surrounding environment is not contaminated by pathogenic micro-organisms, Biosino has established "Biosafety Protection Procedures," including biosafety protection procedures for laboratories and production workshops and emergency response measures. In addition, Biosino has established related documents such as Waste Management Procedures, Personnel Entry and Exit Management Procedures for Production Areas, Site Clearance Management Procedures, and Cleaning Procedures for Containers and Equipment.

During the reporting period, the group implemented a safety production responsibility system at all levels, taking the construction and implementation of the safety management system in the Company and its subsidiaries seriously. Through comprehensive compliance risk assessments, team formation and professional capacity building and enhancement, facility upgrades and renovations, periodic independent inspections and audits, hazard reporting and rectification, and technical support and response for improvement projects, the management has established a regular review system and decision-making mechanism for performance, ensuring the group's lawful, regulated operation and continuous improvement. The group has organized and implemented centralized professional training and other related safety management and improvement activities, significantly reducing the safety risks in its operations, standardizing employee operation management, and deeply embedding safety concepts and culture. In terms of resource conservation and environmentally friendly construction, the group focuses on the application and promotion of energy-saving technologies and energy contract management projects, achieving good economic and environmental benefits.

- **Safety education and training coverage rate: 100%**
- **Safety risk prevention training coverage rate: 100%**
- **Occupational injury insurance coverage rate for employees: 100%**
- **Employee health examination coverage rate: 100%**



- **In 2021-2025, no deaths caused by work accidents occurred;**
- **In 2021, there was one work- related injury;**
- **In 2022-2025, no work-related accidents occurred.**



The organization has implemented occupational health examinations, occupational health training, and occupational health declarations among other occupational health management tasks, ensuring the smooth progress of occupational health management work. In 2025, the monitoring of occupational health factors in the environment was completed, in compliance with industry regulations.

ECOLOGICAL CO-CONSTRUCTION

Strategic Cooperation

On 7 August, Biosino and CR Technology Beijing jointly established an intensive supply chain platform covering the full IVD industry chain, including biochemical diagnostics, flow cytometry products, immunology and molecular diagnostic products, as well as intelligent laboratory solutions. The parties also commenced in-depth cooperation in the medical and healthcare sector to achieve business synergy and enhance core market competitiveness.



On 24 December, the “Dual-Core Drive, Integration for a Shared Future — The First Strategic Integration Conference between BIOBASE and Biosino” was grandly held at BIOBASE Mega Valley in Hainan. As the first significant milestone event following the strategic integration between Biosino and BIOBASE, the conference not only clarified the collaborative direction under the “dual-core drive” strategy, but also established a pragmatic foundation for subsequent industrial integration. Going forward, both parties will take this conference as a new starting point to further strengthen resource integration and business collaboration, and promote high-quality development through deeper integration along the healthcare industry value chain.



On 7 September, Biosino’s subsidiary, Biosino Medical Biotechnology (Shanxi) Co., Ltd. (“**Biosino Medical (Shanxi)**”), was officially established. Leveraging Biosino’s technological strengths and resource support, Biosino Medical (Shanxi) will focus on providing advanced diagnostic products and services to the Shanxi region, thereby contributing to the development of regional healthcare services and supporting the Company’s long-term sustainable development strategy.



EMPOWERING TEAMS AND INDUSTRY GROWTH

On 7 September 2025, the “Precision Medicine Testing Summit Forum”, jointly organised by Biosino Precision Medicine Research Center and Biosino Precision Medical Laboratory, was successfully held in Taiyuan, Shanxi. The forum focused on authoritative academic insights and frontier practice cases, aiming to promote the effective integration of cutting-edge technologies with regional healthcare strategies, accelerate the translation of scientific research findings into clinical applications, and bridge the “last mile” in delivering technological benefits to the public, thereby injecting new momentum into the enhancement of regional healthcare capabilities.

Academician Chen Runsheng of the Chinese Academy of Sciences delivered a keynote speech entitled Big Data and Precision Medicine emphasising that precision medicine has become a strategic high ground in the new round of global scientific and technological competition, with data-driven innovation at its core. He noted that the rapid advancement of AI and its deep integration with healthcare are significantly improving diagnostic accuracy and accelerating the transformation of research achievements. Professor Nie Jinfu, a distinguished expert under the “Hundred Talents Program” of the Chinese Academy of Sciences, shared the latest R&D progress and clinical applications in multi-cancer early screening. By establishing a population-specific methylation fingerprint database and leveraging proprietary technologies, his team developed an innovative multi-omics joint testing solution enabling multi-cancer screening and tissue localisation from a single blood sample, achieving sensitivity and specificity close to 90%.

During the expert dialogue session, discussions centred on precision medicine, big data applications and methylation-based early screening technologies. The experts reached a consensus that promoting early cancer screening represents a highly cost-effective strategic investment, improving patients’ quality of life while alleviating pressure on the healthcare system. Through facilitating academic exchange and clinical collaboration, Biosino further strengthened its role in empowering industry development and enhancing regional diagnostic capabilities, contributing to the sustainable development of the healthcare industry.



SUPPLY CHAIN ESG MANAGEMENT

To ensure suppliers meet the Company's requirements and expectations, and to manage suppliers efficiently, the Company has established a comprehensive supplier management system. The Company conducts supplier management activities in accordance with the "Supplier Evaluation and Control Procedure" and the "Purchasing Control Procedure.“

The "Supplier Evaluation and Control Procedure" enables the effective selection, evaluation, and control of suppliers to ensure that the products and services they provide meet the Company's requirements for production, research and development, testing, and services. The supplier evaluation team, consisting of heads from the Company's quality management department, finance department, reagent factory, purchasing department, R&D department, and quality control department, is responsible for assessing suppliers' quality systems and determining qualified suppliers.

The Company conducts a comprehensive assessment of suppliers' "quality systems" covering aspects such as factory premises, personnel and training, material management, equipment, documentation, production technical management, quality management, subcontracting or subcontracted testing products, delivery, contract signing, and after-sales service. At the same time, based on the "Regulations on the Supervision and Management of Medical Device Production," "Good Manufacturing Practice for Medical Devices," "Guidelines for Medical Device Manufacturer Supplier Audits," and other applicable laws, regulations, and industry standards, the Company sets requirements for suppliers to ensure the quality of supplied products.

For Class A material suppliers, who contribute to the main or critical parts of the Company's final product, approval is given only when they meet requirements in qualifications, quality management system, personnel qualifications, and sample evaluations. Additionally, the purchasing department re-evaluates the qualifications of qualified material suppliers every six months, internally scoring suppliers on supply quality, delivery time, usage, after-sales service, etc., and eliminating suppliers that do not meet standards.

Based on the impact of purchased materials on the Company's products, materials are categorized into three types:

- A-type materials: Main or critical components of the final product that significantly affect the quality or safety performance of the product, mostly including enzymes and antiserums, and materials for internal packaging that come into direct contact with reagents.
- B-type materials: Materials that constitute non-critical parts of the final product, generally not affecting the final product's quality, or if they do have a slight impact, corrective measures can be taken. These are all materials other than A-type materials.
- C-type materials: External packaging materials (labels, packaging boxes, shipping cartons, etc.).

Supply Chain Risk Management

In the realm of supply chain risk identification and management, Biosino has implemented the following measures:

- Risk Identification: The Company regularly assesses supply chain risks, including but not limited to financial stability of suppliers, geopolitical risks, natural disasters, market fluctuations, and supply chain disruptions. Potential supply chain risks are identified through data analysis and market research.
- Risk Assessment: Identified risks undergo quantitative and qualitative analysis to evaluate their potential impact on the Company's supply chain. Risks are categorized and prioritized based on their severity and probability of occurrence.
- Risk Control: For high-risk suppliers, the Company intensifies monitoring and management, taking preventive measures such as increasing inventory, finding alternative suppliers, and signing long-term contracts. Agreements are signed with suppliers to ensure that they bear the risk liability before our Company's acceptance inspection is passed; after passing, the demand side bears the liability, except in cases where the quantity or quality of the internal packaging provided by the supplier does not meet requirements, in which the supplier still bears the risk liability.
- Risk Monitoring: A risk monitoring mechanism is established to regularly track changes in supply chain risks and adjust risk management measures timely. Supplier performance and risk indicators are monitored through data collection and analysis.
- Emergency Plan: An emergency plan for the supply chain is developed to respond to sudden events and crises, ensuring rapid activation of alternative suppliers in the event of supply chain disruptions or other emergencies, minimizing impact on production and operations.
- Continuous Improvement: The supply chain risk management process is continuously optimized through ongoing improvement efforts. Suppliers are encouraged to participate in risk management activities, establishing long-term partnerships to jointly reduce supply chain risks.


Biosino is committed to building a more stable and reliable supply chain system to address various potential risks, ensuring the Company's continued development and competitive advantage.

Raw Material Domestic Substitution


During the reporting period, the Company actively promoted the strategy of substituting domestic materials for imported ones to reduce dependence on external resources and enhance the stability and sustainability of the supply chain. Through strengthening cooperation with domestic suppliers and optimizing procurement processes, the Company has not only successfully reduced costs but also improved the quality and supply efficiency of raw materials. Additionally, domestic substitution helps shorten the supply chain, reduce carbon emissions in logistics, and aligns with our commitment to environmental protection and sustainable development. Key raw materials such as CHE and ADA have been substituted with domestically developed alternatives, and some suppliers from the United States, Japan, and other countries have been replaced with domestic ones, further enhancing the domestic level and competitiveness of our products. We believe that through continuous effort and innovation, we can provide our customers with higher quality, more environmentally friendly products, while positively contributing to national industrial upgrading and green development goals.

- **Domestic supplier proportion: 88.3%**

Summary of Multinational Suppliers by Region



Distribution of Domestic Suppliers by Region



PARTICIPATE IN THE FORMULATION OF INDUSTRY STANDARDS AND GROUPS STANDARDS

For enterprises, participating in the development of national, industry, and group standards holds significant importance. It not only allows them to adjust product quality proactively, seizing market opportunities early on, but also enhances the Company's reputation within the industry and market, thereby building the corporate brand. Furthermore, it can guide the development direction of the industry, and even lead to a repositioning of the industry, increasing market recognition of the Company's products. This, in turn, can expand market share and enhance competitiveness. Currently, Biosino has drafted and published a total of 24 national, industry, and group standards.

Industry standards and group standards

No.	Standard Name	Standard Number	Implementation Date
1	a-Amylase Assay kit (continuous Monitoring Method)	YY/T 1194-2011	2013/6/1
2	Reference Measurement procedure for Total serum protein	YY/T 1195-2011	2013/6/1
3	Purified Water for in vitro Diagnostic Reagents	YY/T 1244-2014	2015/7/1
4	Lactate Dehydrogenase Assay kit	YY/T 1241-2014	2015/7/1
5	a-Hydroxybutyrate Dehydrogenase Assay kit	YY/T 1242-2014	2015/7/1
6	Creatine kinaseAssay kit	YY/T 1243-2014	2015/7/1
7	CystatincAssay kit	YY/T 1230-2014	2015/7/1
8	Alkaline phosphatase Assay kit (Npp substrate-AMp Bufer Method)	YY/T 1234-2014	2015/7/1
9	Total protein Assay kit	YY/T 1444-2016	2017/1/1
10	Lipoprotein (a) Test kit	YY/T 1448-2016	2017/1/1
11	Carbon Dioxide Assay kit	YY/T 1523-2017	2018/4/1
12	C-Reactive protein Assay kit	YY/T 1513-2017	2018/4/1
13	Creatine kinase-MB lsoenzyme Assay kit	YY/T 1580—2018	2019/3/1
14	Heart-Type Fatty Acid-Binding protein Assay kit (lmmunoturbidimetry)	YY/T 1590—2018	2019/3/1
15	Glycated Hemoglobin Assay kit (Latex lmmunoturbidimetry)	YY/T 1605—2018	2019/3/1
16	Allergen-specific lgE Antibody Test kit	YY/T 1581—2018	2019/3/1
17	Uncertainty Evaluation of calibration Material for in vitro Diagnostic Reagents	YY/T 1709—2020	2021/12/1
18	Performance Evaluation Methods for ln vitro Diagnostic Testing systems part 1: precision	YY/T 1789.1-2021	2023/3/1
19	Deafness Gene Mutation Test kit	YY/T 1800-2021	2023/3/1
20	Serum Amyloid A Assay kit	YY/T 1880-2022	2023/10/1
21	Triglyceride Assay kit (Enzymatic) Revision	YY/T 1199—2023	2023/7/15
22	Requirements for Quantitative Measurement of Biogenic samples in vitro Diagnostic Medical Devices and Supporting Documentation for the Glucose Assay Kit (Enzymatic Method)	GB/T 19703-2020	2021/12/1
23	Guide for the Application of value Assignment to ln vitro Diagnostic calibration	T/ZMDs 40001-2021	2021/8/25
24	Materials Glucose Assay Kit (Enzymatic Method)	YY/T 1200-2025	2025/03/01
25	Calibrator for Biochemical Analyzers	YY/T 1549-2025	2025/03/01

EXHIBITION APPEARANCES

Biosino actively participates in important domestic and international exhibitions to showcase its newly launched products and innovative technologies. In 2025, Biosino participated in a total of 7 major domestic and international exhibitions.

(1) In February 2025, Biosino participated in the Dubai International Laboratory Equipment Exhibition in Dubai, showcasing its high-end clinical flow cytometer BioCyte X, together with a range of biochemical diagnostic reagents and related products.

(2) In March 2025, Biosino attended the China Medical Equipment Conference and Medical Equipment Exhibition in Chongqing.

(3) In March 2025, Biosino participated in the 22nd China Association of Clinical Laboratory Practice Expo (CACLP) held in Hangzhou, presenting innovative products including the AutoProSample A960 & BioCyte Fully Automated Flow Cytometry Workstation, the PATHFAST bedside chemiluminescence cardiac marker analyser, adiponectin testing products and a series of biochemical diagnostic reagents.

(4) From August to September 2025, Biosino participated in the 22nd China Heart Congress (CHC 2025) in Beijing, exhibiting the PATHFAST fully automated bedside cardiac marker analyser.

(5) In September 2025, Biosino attended the 19th Academic Conference on Laboratory Medicine organised by the Beijing Medical Association, showcasing its newly launched BioCyte X (4-laser, 21-colour) flow cytometer, the AutoProSample A960 & BioCyte Fully Automated Flow Cytometry Workstation, the PATHFAST bedside chemiluminescence cardiac marker analyser, adiponectin testing products and a comprehensive range of biochemical diagnostic reagents.

(6) In November 2025, Biosino participated in CCLM 2025 Cardiovascular Laboratory Medicine Conference held in Guangzhou.

(7) In November 2025, Biosino attended MEDICA in Düsseldorf, Germany, one of the world's leading trade fairs for the medical industry, where it exhibited the BioCyte X (4-laser, 21-colour) flow cytometer.



COMMUNITY INVOLVEMENT

To ensure the safety of travel for people within the industrial park and surrounding community, the Company promptly organized employees to carry out a volunteer snow removal and de-icing initiative following the snowfall. Working together, our team cleared accumulated snow from the roads to ensure smooth passage for both vehicles and pedestrians, safeguarding community safety and order through concrete actions.



APPENDIX I: INDEX TABLE OF HKEX ESG REPORTING GUIDE

Subject Areas' Aspects' General Disclosures and KPIs		chapter and page
A. Environment		
Aspect A1	**Emissions**	
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to air emissions, discharges into water and land, and generation of hazardous and non-hazardous waste. Note: Air emissions include NOx, SOx, and other pollutants regulated under national laws and regulations. Hazardous wastes are those defined by national regulations.	P24-25 P30
KPI A1.1	The types of emissions and respective emissions data.	P26-27 P30
KPI A1.2	Total hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	P30
KPI A1.3	Total non-hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	P30
KPI A1.4	Description of emission target(s) set and steps taken to achieve them.	P24-28
KPI A1.5	Description of how hazardous and non-hazardous wastes are handled, and a description of reduction target(s) set and steps taken to achieve them.	P24/P29
Aspect A2	**Use of Resources**	
General Disclosure	Policies on the efficient use of resources, including energy, water and other raw materials. Note: Resources may be used in production, in storage, transportation, in buildings, electronic equipment, etc.	P30
KPI A2.1	Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total (kWh in '000s) and intensity (e.g. per unit of production volume, per facility).	P30
KPI A2.2	Water consumption in total and intensity (e.g. per unit of production volume, per facility).	P30
KPI A2.3	Description of energy use efficiency target(s) set and steps taken to achieve them.	P24/P29
KPI A2.4	Description of whether there is any issue in sourcing water that is fit for purpose, water efficiency target(s) set and steps taken to achieve them.	P24/P29
KPI A2.5	Total packaging material used for finished products (in tonnes) and, if applicable, with reference to per unit produced.	P30
Aspect A3	**The Envionment and Natural Resources**	
General Disclosure	Policies on minimising the issuer's significant impacts on the environment and natural resources.	P30
KPI A3.1	Description of the significant impacts of activities on the environment and natural resources and the actions taken to manage them.	P24-25/P29-30
Aspect A4	**Climate Change**	
General Disclosure	Policies on identification and mitigation of significant climate-related issues which have impacted, and those which may impact, the issuer.	P25
KPI A4.1	Description of the significant climate-related issues which have impacted, and those which may impact, the issuer, and the actions taken to manage them.	P24-29

APPENDIX I: INDEX TABLE OF HKEX ESG REPORTING GUIDE

Subject Areas' Aspects' General Disclosures and KPIs		chapter and page
B. Social		
Aspect B1	**Employment**	
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to compensation and dismissal, recruitment and promotion, working hours, rest periods, equal opportunity, diversity, anti-discrimination, and other benefits and welfare.	P31-32
KPI B1.1	Total workforce by gender, employment type (for example, full- or part-time), age group and geographical region.	P32-33
KPI B1.2	Employee turnover rate by gender, age group and geographical region.	P33
Aspect B2	**Health and Safety**	
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to providing a safe working environment and protecting employees from occupational hazards.	P36
KPI B2.1	Number and rate of work-related fatalities occurred in each of the past three years including the reporting year.	P36
KPI B2.2	Lost days due to work injury.	P36
KPI B2.3	Description of occupational health and safety measures adopted, and how they are implemented and monitored.	P36
Aspect B3	**Development and Training**	
General Disclosure	Policies on improving employees' knowledge and skills for discharging duties at work. Description of training activities. Note: Training refers to vocational training. It may include internal and external courses paid by the employer.	P34-35
KPI B3.1	The percentage of employees trained by gender and employee category (e.g. senior management, middle management).	P35
KPI B3.2	The average training hours completed per employee by gender and employee category.	P35
Aspect B4	**Labour Standards**	
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to preventing child and forced labour.	P35
KPI B4.1	Description of measures to review employment practices to avoid child and forced labour.	P32/P35
KPI B4.2	Description of steps taken to eliminate such practices when discovered.	P35
Aspect B5	**Supply Chain Management**	
General Disclosure	Policies on managing environmental and social risks of the supply chain.	P38-39
KPI B5.1	Number of suppliers by geographical region.	P40

APPENDIX I: INDEX TABLE OF HKEX ESG REPORTING GUIDE

Aspect B5	**Supply Chain Management**	
KPI B5.2	Description of practices relating to engaging suppliers, number of suppliers where the practices are being implemented, and how they are implemented and monitored.	P40
KPI B5.3	Description of practices used to identify environmental and social risks along the supply chain, and how they are implemented and monitored.	P39
KPI B5.4	Description of practices used to promote environmentally preferable products and services when selecting suppliers, and how they are implemented and monitored.	P38-40
Aspect B6	**Product Responsibility**	
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to health and safety, advertising, labelling and privacy matters relating to products and services provided and methods of redress.	P16-17
KPI B6.1	Description of practices used to promote environmentally preferable products and services when selecting suppliers, and how they are implemented and monitored.	P20
KPI B6.2	Number of products and service related complaints received and how they are dealt with.	P23
KPI B6.3	Description of practices relating to observing and protecting intellectual property rights.	P18-19
KPI B6.4	Description of quality assurance process and recall procedures.	P20-21/P23
KPI B6.5	Description of consumer data protection and privacy policies, and how they are implemented and monitored.	P20
Aspect B7	**Anti-corruption**	
General Disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.	P11
KPI B7.1	Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.	P11
KPI B7.2	Description of preventive measures and whistle-blowing procedures, and how they are implemented and monitored.	P11
KPI B7.3	Description of anti-corruption training provided to directors and staff.	P11
Aspect B8	**Community Investment**	
General Disclosure	Policies on community engagement to understand the needs of the communities where the issuer operatesand to ensure its activities take into consideration the communities'interests.	P42
KPI B8.1	Focus areas of contribution (e.g. education, environmental concerns, labour needs, health, culture, sport).	P38/P48
KPI B8.2	Resources contributed (e.g. money or time) to the focus area.	P42

READER FEEDBACK

Dear Reader,

Thank you for reading this report. This is the fifth consecutive year that Biosino has disclosed environ-mental, social, and governance (ESG) information, and it is the first time we have independently published an ESG report. we sincerely hope that you can evaluate this report and provide us with your valuable feedback to help us continuously improve.

Feedback survey:

Did you find the information you needed in this report?

What additional information do you think should be included in this report?

Do you have any other suggestions for this report?

Contact person: Yue Zhang

Address: No. 27, chaoqian Road, changping District, Beijing

Email: zhangyue@zhongsheng.com.cn

中生北控生物科技股份有限公司
BIOSINO BIO-TECHNOLOGY AND SCIENCE INC